Role of a third generation calcium antagonist in the management of hypertension.
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 57 (1), 1-10
- https://doi.org/10.2165/00003495-199957001-00001
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Safety Profile of LacidipineDrugs, 1999
- Maintained autonomic responses to moderate exercise in hypertensive patients treated with lacidipineJournal Of Hypertension, 1997
- Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionThe Lancet, 1997
- Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1996
- Shanghai trial of nifedipine in the elderlyJournal Of Hypertension, 1996
- The Risk of Myocardial Infarction Associated With Antihypertensive Drug TherapiesJAMA, 1995
- Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation.1995
- Current status of calcium channel blockersCurrent Problems in Cardiology, 1994
- Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to dispositionClinical Pharmacology & Therapeutics, 1990
- Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule.1987